The integration of temozolomide (TMZ) chemotherapy into therapy for newly diagnosed glioblastoma multiforme (GBM) has a major impact on survival for a subset of patients. Unfortunately, essentially all patients develop resistance to TMZ, and consequently, understanding the mechanisms of TMZ resistance development is critically important. Using primary GBM xenograft models, we have demonstrated that acquired TMZ resistance can be induced by 2 distinct mechanisms within the same tumor with one mechanism being driven by increased histone acetylation within the promoter of a critical DNA repair protein MGMT. Moreover, co-treatment with the histone deacetylase inhibitor SAHA promotes development of this epigenetically-driven resistance mechanism. Whole exome-seq and RNA-seq in TMZ-resistant models without MGMT elevation identified mutations in DNA ligase IV, Ku70 and Ku80, which are key components in the non-homologous end-joining (NHEJ) DNA repair pathway. Consistent with defects in this critical pathway, these mutations were associated with delayed DNA repair kinetics and a paradoxical increase in radiation responsiveness. The focus of this application is to investigate these 2 distinct mechanisms of TMZ resistance emergence using our patient derived xenograft models and patient tumor tissues. The planned aims are:
AIM 1 : Define the changes in the chromatin-modifying complexes regulating MGMT upregulation. Our preliminary data suggest that distinct chromatin modifying complexes suppress MGMT expression in different MGMT-methylated GBM xenograft lines, and we hypothesize that the specific resident complex within the MGMT promoter will define the effects of epigenetically-targeted therapies on MGMT up-regulation.
AIM 2 : Test whether DNA damage-induced alterations in heterochromatin promote evolution of TMZ resistance. DNA damage induced by TMZ or radiation triggers a highly orchestrated DNA damage response that includes chromatin remodeling, and we hypothesize that MGMT upregulation requires focal chromatin opening within the MGMT promoter in association with damage repair AIM 3: Define whether deregulation of DNA repair contributes to mechanisms of TMZ resistance in MGMT non-expressing tumors. Based on our previous work demonstrating that suppression of NHEJ activity can abrogate the cytotoxicity of PARP inhibitors, we hypothesize that a similar disruption of NHEJ through acquired mutations contributes to TMZ resistance, while leading to an increase in radiation responsiveness. Defining the mechanism(s) of TMZ resistance associated with radiation hypersensitivity may provide a strategy for selecting patients most likely to benefit from re-irradiation following tumor progression.

Public Health Relevance

Temozolomide (TMZ) is an important chemotherapy agent for glioblastoma (GBM) that provides significant survival gains when combined with radiation in newly diagnosed patients. Unfortunately, essentially all patients develop resistance to TMZ, which ultimately limits survival for patients with this devastating disease. The planned studies will investigate two different mechanisms of TMZ resistance emergence. Both of these mechanisms will provide important mechanistic insights that could lead to novel treatment strategies to prevent resistance emergence and significantly extend survival for these patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA176830-01
Application #
8515591
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Okano, Paul
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
1
Fiscal Year
2013
Total Cost
$329,925
Indirect Cost
$122,425
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Kizilbash, Sani H; Gupta, Shiv K; Chang, Kenneth et al. (2017) Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 16:2735-2746
Müller-Greven, Gaëlle; Carlin, Cathleen R; Burgett, Monica E et al. (2017) Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival. Clin Cancer Res 23:7059-7071
Nagel, Zachary D; Kitange, Gaspar J; Gupta, Shiv K et al. (2017) DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res 77:198-206
Hashizume, Rintaro; Zhang, Ali; Mueller, Sabine et al. (2016) Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol 18:1519-1528
Gupta, Shiv K; Kizilbash, Sani H; Carlson, Brett L et al. (2016) Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst 108:
Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98
Pokorny, Jenny L; Calligaris, David; Gupta, Shiv K et al. (2015) The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res 21:1916-24
Ramirez, Yulian P; Mladek, Ann C; Phillips, Roger M et al. (2015) Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther 14:111-9
Pastori, Chiara; Daniel, Mark; Penas, Clara et al. (2014) BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 9:611-20